We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Stock analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects ...

UTHR currently has a forward P/E ratio of 12.63, while ZTS has a forward P/E of 27.56. We also note that UTHR has a PEG ratio of 0.92. This metric is used similarly to the famous P/E ratio, but the ...

Another notable valuation metric for UTHR is its P/B ratio of 2.65. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its ...

BTIG analyst Julian Harrison maintained a Hold rating on United Therapeutics (UTHR – Research Report) on January 21. The company’s shares ...

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang ...